CRVS

CRVS AI Signal Analysis

Multi-agent conviction signals powered by SEC filings, insider trades, institutional holdings, and earnings data

1signals

avg conviction-6

0/0

Mar 27, 2026

conviction

Neutral(low)

Corvus Pharmaceuticals faces meaningful near-term headwinds driven by a 13.7% EPS miss and sharply deteriorating operating cash flow of -$33M (down 29% YoY), which signals accelerating cash burn that outweighs the reported 75.5% improvement in net loss. Options positioning shows structurally bullish open interest (25,958 calls vs. 6,511 puts), yet recent bearish sweep flow and a 14.62% put-IV premium over call IV suggest sophisticated participants are hedging downside risk. With one forensic accounting flag under monitoring and no institutional or insider signals to anchor conviction, the risk/reward does not favor directional positioning at current levels. The setup warrants a wait-and-see approach pending clarity on cash runway and upcoming clinical catalysts.

-12

-10

-6

Agent Breakdown

Fundamentals AgentBearish

-18

The most recent quarter showed a 13.7% EPS miss alongside deteriorating operating cash flow of -$33M (down 29.0% YoY), signaling worsening cash burn despite a 75.5% YoY improvement in net loss to -$15M; the cash flow deterioration is the more concerning signal as it suggests underlying operational stress. One forensic accounting flag warrants monitoring but is not yet alarming given the 80/100 cleanliness score.

Sources

ForensicForensic score: 80/100 (1 flags)
EarningsEPS surprise: -13.7% (est -0.13, actual -0.15)
Analyst RatingAnalyst consensus: 5 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell

Options AgentBullish

+12

Call volume dominates at 2,562 vs. 897 puts (P/C ratio 0.35) with OI heavily skewed 25,958 calls vs. 6,511 puts, suggesting structural bullish positioning, though bearish sweep dollar flow ($21.4K net bearish over 48h) and a 14.62% put-IV premium (ATM put IV 96.3% vs. call IV 81.7%) indicate meaningful demand for downside protection that tempers conviction.

Sources

IV DataIV metrics: 0.0% percentile, IV/HV ratio 1.07

Unlock agent-level analysis

See exactly what each AI agent found — forensic accounting flags, insider clusters, institutional shifts, and more.

Get started View pricing

Trade Plan

Live Return

$14.01-2.0%

Entry: $14.30 · 1d elapsed / 180d horizon

Tracking

Entry Zone

In entry zone

$13.80

$14.50

Valid until Apr 10, 2026

Price Targets (180-day)

Bull

$18.50+32.0%

Positive clinical data readout or partnership announcement could re-rate the stock toward prior resistance near $18-19.

Base

$15.20+8.5%

Modest mean reversion toward recent range midpoint assuming no material news and stable cash position.

Bear

$11.00-21.5%

Continued cash burn acceleration or negative trial data could push shares toward $11, near 52-week support levels.

Stop Loss

$12.50

-10.8%

Position Size

1-2%

of portfolio

Risk/Reward

1.1x

base target

Unlock the trade plan

Get entry zones, price targets, stop loss levels, and position sizing for every signal.

Get started View pricing

Get the full picture on CRVS

Our AI analyst team runs 5 specialized agents on every stock. Unlock detailed breakdowns, trade plans, and real-time alerts.

Start for $9/mo View pricing

Not financial advice. For informational purposes only. Past performance does not guarantee future results.